Navigation Links
Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/4/2011

PRINCETON, N.J., Jan. 4, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the 29th Annual J.P. Morgan Healthcare Conference to be held January 10-13, 2011 at the Westin St. Francis Hotel, San Francisco, CA. Schaefer Price, President and Chief Executive Officer, will provide an overview of the company on Wednesday, January 12, 2011 at 9:00 AM (PT).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have four clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in tw
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... BRIDGEWATER, N.J. , Sept. 22, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today is pleased to announce that TUV-SUD ... the Netherlands (MEB) has granted its ... catheter lock solution.  Neutrolin was initially approved in ...
(Date:9/22/2014)... DALLAS and NEW YORK ... PHARMACEUTICALS, INC. (OTCBB: ACCP), has signed an exclusive, ... for the development and commercialization of its proprietary ... new corporate management team and its intention to ... Biopharmaceuticals, Inc.™, and its plans to pursue a ...
(Date:9/22/2014)... DENVER , Sept. 22, 2014  Prostate cancer ... men, but it is easily treated when caught early ... not. That is why the Prostate Conditions Education ... men,s health and a leader in prostate cancer screening ... Cancer Awareness Week (PCAW) from September 22-27.  ...
Breaking Medicine Technology:Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 2PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 3
... Patent Protects Very Low Dose Glucagon ahead of Phase 2 Clinical Trials ... ... SAN FRANCISCO, Jan. 8 DiObex, Inc., a privately held,biotechnology company developing ... from the U.S. Patent,and Trademark Office for the use of very low ...
... BOTHELL, Wash., Jan. 8 Nastech Pharmaceutical,Company Inc. ... enrollment for its,Phase 2 clinical trial of PYY3-36 ... obese patients at multiple clinical sites in the ... study. The,study is designed to evaluate three different ...
Cached Medicine Technology:DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia 2Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity 2Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity 3
(Date:9/22/2014)... whole eye transplant seems futuristic, if not impossible. ... Department of Defense, researchers at University of California, ... make implantation of an entire, functional eye a ... a holy grail for vision restoration," said Jeffrey ... co-recipient with colleagues at University of Pittsburg Medical ...
(Date:9/22/2014)... living in Canada have a higher rate of heart ... while people, McMaster researchers have found. , The ... Association Journal (CMAJ Open) and may be found ... ethnic groups in the country is the more than ... about three percent of the population. They include people ...
(Date:9/22/2014)... -- Recent two-generation approaches to reducing poverty that ... attention from researchers, advocates, and foundations. By combining ... to move to jobs that offer a path ... education for children, these programs aim to improve ... to a new report from the National Center ...
(Date:9/22/2014)... 22, 2014 The R&D of cancer ... years. The statistically important data received from clinical research ... vaccines. The primary challenge to the development of such ... exact mechanism of how a human’s immune system works. ... in different individuals owing to known factors with genetics ...
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Scans ... they learn to read. This finding could potentially ... other reading difficulties early on, preliminary research suggests. ... in children with dyslexia as well as most ... Hoeft, an associate professor of child and adolescent ...
Breaking Medicine News(10 mins):Health News:Looking ahead: Whole eye transplant under development 2Health News:Higher risk of heart disease for South Asians in Canada 2Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2
... Researchers and staff from Karolinska Institutet are contributing ... of everything from neuroscience to bioentrepreneurship. Carl Johan ... Institutet, is the founder and initiator of ESOF. ... decision-makers, researchers, journalists and the general public meet ...
... ... dedicated to ending malaria deaths and empowering communities, ONE bracelet at a time (Buy a ... Malaria, and encourages others to join in the fight against this deadly disease. Malaria is ... kills a child every 30 seconds. , ...
... suggests that shorter length of leukocyte telomeres chromosome markers ... of cancer and death from cancer, according to a study ... leukocyte is a type of blood cell. Telomeres are ... the replication and stability of the chromosome. Genetic factors and ...
... COLUMBUS, Ohio Scientists have designed a nanoparticle that appears ... effects. In lab experiments, the researchers have found that ... enough into a cell to allow genetic material to be ... is between 2 and 10 times more effective than ...
... linked rejection by a romantic partner to brain activity associated ... published in the July issue of the Journal of ... R. Korey Department of Neurology and of neuroscience at Albert ... author of the study. This is the third publication in ...
... ... of additional foot problems such as bunions, hammertoes, arthritis and calluses, and improve a ... Ankle Surgery. , ... Chicago, IL (Vocus) July 6, 2010 -- Treatment and prevention of adult flatfoot can ...
Cached Medicine News:Health News:News from Karolinska Institutet at ESOF 2010 2Health News:MALAIKA FOR LIFE Takes a Stand in Light of Cheryl Cole's Malaria Bout 2Health News:MALAIKA FOR LIFE Takes a Stand in Light of Cheryl Cole's Malaria Bout 3Health News:Length of biological marker associated with risk of cancer 2Health News:Scientists design new delivery device for gene therapy 2Health News:Scientists design new delivery device for gene therapy 3Health News:Scientists design new delivery device for gene therapy 4Health News:Study links romantic rejection with reward and addiction centers in the brain 2Health News:Don't Ignore Flat Feet,Study links this condition to painful foot maladies 2
Stainless steel flexible ruler. graduated in 1/32 inches (.8 mm) fractions, as well as mm graduations....
At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....
Rigid Endoscopes....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: